CA Patent

CA3152557A1 — Solid dispersions containing an apoptosis-inducing agent

Assigned to AbbVie Inc · Expires 2012-05-03 · 14y expired

What this patent protects

A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bc1-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharm…

USPTO Abstract

A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bc1-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bc1-2 family proteins, for example cancer.

Drugs covered by this patent

Patent Metadata

Patent number
CA3152557A1
Jurisdiction
CA
Classification
Expires
2012-05-03
Drug substance claim
No
Drug product claim
No
Assignee
AbbVie Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.